

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000261

International filing date: 27 January 2005 (27.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0401821.4  
Filing date: 28 January 2004 (28.01.2004)

Date of receipt at the International Bureau: 25 February 2005 (25.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



POT/GB2005/000261



INVESTOR IN PEOPLE


The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Stephen Hordley*

Dated 11 February 2005

Patents Act 1977  
Rule 16)

**Patent  
Office**

28 JAN 04 E868966-1 802776  
P01/7700 0.00-0401821.4 ACCOUNT CHA

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

THE PATENT OFFICE  
RM  
28 JAN 2004  
RECEIVED BY FAX  
QIP/P7334

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

2. Patent application number  
(The Patent Office will fill in this part)

28 JAN 2004

0401821.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

QINETIQ NANOMATERIALS LIMITED

Registered Office 85 Buckingham Gate  
London SW1E 6PD  
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

GB

8540398001

4. Title of the invention

Method of manufacture of polymer composites

5. Name of your agent (if you have one)

Ian Michael JOHNSON

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

QINETIQ LIMITED  
IP Formalities  
A4 Bldg  
Cody Technology Park  
Ively Road  
Farnborough  
Hants GU14 0LX United Kingdom

8183873001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number or earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right if to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.  
See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description 13

Claim(s) 3

Abstract 1

Drawing(s) 5

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I / We request the grant of a patent on the basis of this application.

Signature

I.M. Johnson, Agent for the Applicant

Date: 28.01.2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs Linda Bruckshaw 01252 392722

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent of the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have attached 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

0092946 28-Jan-04 04:05

DUPLICATE

1

## METHOD OF MANUFACTURE OF POLYMER COMPOSITES

The present invention relates to a method of manufacturing a polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein, and products relating thereto. In particular, the present invention relates to anti-microbial fibres and films incorporating metal nanoparticles, and more especially to alginate/silver fibres, and fabrics and wound dressings made therefrom.

Many metals, including transition metals, have been applied to fibres, especially polymeric fibres, so as to produce textiles and other materials that exhibit beneficial properties. The metal may be applied to the fibre substrate either in its metallic form or as a salt or compound, and typical methods of application include vapour deposition, sputtering, coating, spraying, chemical reactions and the use of adhesives. Such methods tend, however, to be inefficient and costly and may result in the release of toxic metals into the environment. Furthermore, because the metal or metal compound is typically only present at the fibre surface, the required material property is not generally permanent; in other words, the property degrades with time.

One such example of a beneficial property is antimicrobial activity, and polymeric fibres incorporating antimicrobial metals are known for the production of wound dressings, surgical apparel and other antimicrobial materials. Many metals exhibit antimicrobial effects, for example Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi and Zn, and their mode of action is typically due to the interference of the metal ion with electron donating functional groups present in microbiological molecules. The antimicrobial metal may be applied to the fibres either in its metallic form or, more commonly, as a metal compound. In either case, the release of the active ion is typically triggered by contact with biological fluids.

Ag, in particular, has long been established as an effective anti-microbial agent and is widely used in bio-medical products

to control infection. Usually a silver salt or compound, such as silver nitrate, is used as the active agent in antimicrobial fibres, particularly in applications involving the use of a hydrophilic substrate, such as wound dressings. Use of the metal itself in wound dressings and such-like is generally undesirable, because of the inherent hydrophobicity of metal coatings etc.

However, certain disadvantages are associated with the use of silver compounds in bio-medical applications, including photosensitivity, toxic effects such as hypochloremia and hyperpyrexia, transient discoloration of patients skins and rapid dissipation (leaching) of the antimicrobial agent.

An object of the present invention is to provide antimicrobial fibres which retain their hydrophilic and antimicrobial properties, whilst avoiding side effects associated with metal compounds, particularly silver compounds.

According to a first aspect of the present invention, there is provided a method of producing a polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein, said method comprising the steps of:

- (i) mixing metal nanoparticles with a polymer dope; and
- (ii) solidifying the polymer composite from the dope.

A polymer dope typically comprises a solvent and a polymer, and is formed by mixing those ingredients in a mixer. A polymer dope can be used as a means of solidifying the polymer into various forms, such as, for example, fibres, threads or other extruded shapes, sheets, films, membranes or cast shapes. The polymer may be reconstituted, or solidified, from the solvent by various means, for example by coagulation or by solvent evaporation. Two common examples of the use of a polymer dope are; firstly, in conjunction with a spinning technique to form threads and fibres; and, secondly, casting the dope into a film, sheet or membrane by spreading the dope onto a surface with a doctor blade.

Metal nanoparticles are metal particles having nanometric dimensions, and may have, for example, dimensions in the order of a few nanometres to several hundred nanometres. The metal nanoparticles may be spherical or aspherical, and may also be known as a metal nanopowder or as a nanometric metal. The metal nanoparticles used in the present invention may comprise a metal, a metal alloy or a metalloid, or any combination thereof.

The present inventors have realised that, by incorporating metal nanoparticles into a polymer dope prior to reconstituting the polymer from the dope, the metal and polymer can be co-solidified so as to form a composite polymeric material having metal nanoparticles incorporated therein. The composite material thus-formed comprises a continuous polymer phase, or matrix, throughout which the metal nanoparticles are embedded, and is referred to herein as a polymer composite. Polymer composites manufactured according to the present invention can be made in a simple and cost effective manner, with little wastage of expensive metal starting materials.

Furthermore, by selecting specific combinations of metal nanoparticles and polymer matrix, polymer composites having a wide range of desirable properties can be obtained.

Preferably, the polymer composite is formed by an extrusion method, in which case the polymer and metal nanoparticles are co-extruded so as to form an extruded composite material. Advantageously, the polymer composite is extruded in the form of a fibre, or thread, so that a fibre comprising a polymer matrix incorporating metal nanoparticles is obtained. Alternatively, the polymer may be extruded in the form of a thin sheet or film. The present invention is of particular benefit where the extruded polymer composite has dimensions of microns or even nanometers, due to the small size of the metal particles.

Preferably, the nanoparticles have a particle size less than 500 nm, more preferably less than 200 nm and even more preferably less than 100nm. In Example 1, the particle size distribution was  $d_{90} < 70\text{nm}$ ,  $d_{50} < 50\text{nm}$  and  $d_{10} < 40\text{ nm}$ . Most preferably, the particle size is in the range 20 to 100 nm

In some instances the nanoparticles may be spherical, but for some applications aspherical particles, for example rods, may be preferred. Non-regular features on the particle surface, such as angles or spikes, may be desirable, for example where  
5 electrical conductivity is required.

The metal nanoparticles may be added to the solvent before preparing the polymer dope, or, more preferably, the polymer dope is fully prepared prior to adding the metal nanoparticles. The inventors have found that it is particularly important to add the  
10 metal nanoparticles after preparing the dope in instances where the metal may interfere with the solubility of the polymer, for example where the metal concentration is relatively high. In either case, the metal nanoparticles may be added in a continuous or batchwise fashion.

15 Advantageously, the dope solution is stirred vigorously so as to produce a homogeneous polymer/nanoparticle mixture, using, for example, a high shear mixer. The benefits of forming a homogeneous mixture are, firstly, that the metal nanoparticles are uniformly dispersed across the cross-section of the extruded  
20 polymer composite and, secondly, that particle agglomeration is controlled.

A dispersant or surfactant, for example an alcohol-based dispersant, may be added to the dope solution to control agglomeration of the metal nanoparticles, such that agglomeration  
25 is reduced or even substantially prevented. Alternatively, agglomeration can be controlled by sonification or similar techniques.

The amount of metal nanoparticles added to the dope depends upon the required application and the type of polymer selected as  
30 the matrix material. Typically, silver is added to an alginate polymer in an amount between 0.1 and 15 % w/w, and to a matrix comprising cellulose in an amount up to about 5 % w/w.

The polymer matrix may comprise a synthetic polymer, a natural polymer or any combination thereof. Suitable natural  
35 polymers are polysaccharides such as cellulose, alginate, chitin or chitosan. A single natural polymer may be used, or a mixture



of natural polymers, for example sodium alginate mixed with carboxymethyl cellulose, pectin or xanthan.

Any synthetic polymer which is suitable for use in the chosen process can be used, such as, for example, polyethylene  
5 (PE), polyethylene terephthalate (PET), nylon, acrylic, rayon, Spandex, polyolefins, polyurethane and electromeric polymers such as Lycra. Examples of synthetic polymers that are suitable for solution spinning are polyacrylonitrile, acetate fibres or viscose fibres, but the choice of polymer is not limited to those  
10 examples.

The concentration of polymer in the dope depends on the polymer used and the application. In Example 1, 5-7 % w/w alginate polymer was used to form silver/alginate fibres.

The metal nanoparticles preferably comprise a transition  
15 metal, but may comprise any other metal, metal alloy or metalloid, or any combination thereof, which exhibits the properties required in the extruded polymer composite.

Preferably, the metal nanoparticles have antimicrobial properties and are selected from Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb,  
20 Bi or Zn, or alloys or combinations thereof. More preferably, the metal nanoparticles have antimicrobial properties and comprise silver.

Alternatively, the metal nanoparticles may be selected so as to impart, for example, electrical or thermal conductivity,  
25 magnetism or improved fire retardancy to the extruded polymer. Examples of metal nanoparticles that impart magnetic properties are Co, Fe, Cu and NdFeB alloy.

In a preferred embodiment of the present invention, the metal nanoparticles comprise silver and the polymer matrix  
30 comprises alginate. Suitably, the silver is present in the alginate matrix in an amount between 0.1 and 15 % w/w, more preferably between 0.1 and 2 % w/w. In applications where a hydrophilic polymer is used, such as alginate, the amount of metal in the fibre is preferably kept low so that the water  
35 absorption properties of the fibre are not inhibited.

Preferably the polymer composite is extruded, and more preferably the polymer composite is extruded into the form of fibres. By varying the concentration of metal nanoparticles mixed with the polymer dope during the extrusion process, fibres and  
5 other extruded products may be obtained having a metal concentration that varies along the extruded length.

Fibres may be extruded from the polymer dope by any suitable technique, but, preferably, polymer composite fibres are extruded by a spinning technique such as, for example wet spinning, dry  
10 spinning or dry-jet wet spinning. In wet spinning, the dope solution is extruded through a spinneret which is completely immersed in a coagulant. In dry-jet wet-spinning a spinneret is also employed, but a small air gap is left between the spinneret face and the surface of the coagulant, the length of air gap  
15 depending on the polymer concentration and viscosity. A dry spinning technique tends to be preferred for polymers dissolved in a volatile solvent, whereas wet spinning or dry-jet wet spinning is more suitable for aqueous or non-volatile dope solutions.

20 Advantageously, the dope solution is de-aerated before extrusion, for example either under vacuum or by leaving the solution to stand in an inert atmosphere. Preferably, where a spinning technique is used, the polymer solution is also filtered prior to extrusion, so as to prevent blockage of the spinneret.  
25 The type of filtration system used depends on the spinneret hole diameter and the type and size of the particles that need to be removed from the solution. The filter system is preferably arranged behind the spinneret, and may be positioned in the spinneret holder. One preferred filter system comprises a wire  
30 mesh of size 150-500 micron, optionally arranged together with a thin, non-woven, or plain woven, fabric which is insoluble in the dope solution. Advantageously, an additional cartridge filter is positioned upstream of the spinneret.

Different types of spinnerets can be used for the production  
35 of polymer composite fibres, depending on the properties required in the final fibres; for example, geometric spinnerets can be

used to obtain different cross-sectional shapes. For wet spinning, spinnerets with hole diameters less than 100 micron are preferable, more preferably between 60 and 90 micron. For dry spinning and dry-jet wet spinning, the holes are usually spaced  
5 out from each other to avoid the fluid filaments twinning during extrusion. Furthermore, the hole diameters are usually bigger than those used for wet spinning and range mostly above 100 micron.

For wet spinning, a coagulant containing a small amount of  
10 the solvent at or below ambient temperature is typically employed. For cellulose, for example, water or water containing a small amount of N-methylmorpholine-N-oxide (NMMO) at about 50 to 80 °C is typically employed as a coagulant. For alginate, aqueous Ca<sup>2+</sup> is commonly used as the coagulant. For dry-jet wet spinning,  
15 the coagulant is the same as for wet spinning except that the bath could be at any temperature between 5 and 80°C. In all cases, the amount of NMMO in the coagulant is increased as extrusion progresses.

According to a second aspect of the present invention, there  
20 are provided fibres comprising a polymer matrix having at least one metal incorporated therein, wherein the at least one metal is in the form of nanoparticles.

The present inventors have found that, by selecting certain combinations of polymer matrix and metal nanoparticles, composite  
25 fibres exhibiting a wide range of desirable properties can be obtained, for a variety of different applications; examples of fibres so-obtained are antimicrobial fibres, heat conducting fibres, electrically conductive fibres and magnetic fibres.

The metal nanoparticles are preferably distributed across  
30 the fibre cross section in a substantially uniform manner. In some applications, the concentration of metal particles distributed along the fibre length may be constant, but, alternatively, the concentration of metal particles along the fibre length may vary. In some instances, fibres according to the  
35 present invention may comprise one or more lengths of the base polymer in combination with one or more lengths of the polymer

matrix incorporating metal nanoparticles. Thus, polymer fibres may be obtained that exhibit the required property either throughout their whole length or along part of their length.

5 There may be a degree of nanoparticle agglomeration in the polymer matrix, and, typically, nanoparticle agglomerates may be from 100 nm to 2 microns in size. For some applications, it may be preferable that agglomeration is controlled or even substantially avoided, so that the nanoparticles are evenly distributed throughout the polymer matrix.

10 In the case of hydrophilic fibres used in antimicrobial wound dressings and the like, particularly silver/alginate fibres, the gradual absorption of aqueous exudate into the polymer matrix leads to a gradual degradation of the matrix. By incorporating antimicrobial particles throughout the fibre  
15 according to the present invention, said particles are gradually released as the fibre absorbs fluid, thereby providing a controlled, slow release of the metal antimicrobial agent.

The fibres may have any diameter suitable for a given application, but typically the fibre diameter is less than 500  
20 microns, more preferably less than 100 microns and most preferably 10 to 50 microns. Antimicrobial fibres for use in wound dressings, in particular, require fibre diameters in the above-mentioned ranges.

In some applications, the fibre may further comprise an  
25 outer protective sheath or coating.

In accordance with a third aspect of the present invention, there is provided a wound dressing comprising fibres according to the present invention. Preferably the wound dressing is a non-woven wound dressing.

30 In accordance with a fourth aspect of the present invention, there is provided a film comprising a polymer matrix having metal nanoparticles incorporated therein.

In accordance with a fifth aspect of the present invention, there is provided a polymer composite comprising a polymer matrix  
35 having metal nanoparticles incorporated therein.

A preferred embodiment of the present invention will now be described, with reference to the accompanying drawings in which:

Figure 1 is a schematic sectional view of a preferred apparatus for wet-spinning composite fibres according to the present invention;

Figure 2 shows a SEM spectrum of the longitudinal outer surface of a prior art alginate fibre;

Figure 3 shows a SEM spectrum of the longitudinal outer surface of an alginate fibre incorporating 5 % w/w silver nanoparticles according to the present invention;

Figure 4 shows a SEM spectrum of the longitudinal outer surface of an alginate fibre incorporating 15 % w/w silver nanoparticles according to the present invention; and

Figure 5 shows a SEM spectrum of a cross-section of an alginate fibre incorporating 15 % w/w silver nanoparticles according to the present invention.

Fibres comprising an alginate matrix having silver nanoparticles incorporated therein can be used in biomedical applications such as wound dressings.

Alginate is a linear polysaccharide made up of two uronic acid monomers, mannuronic acid (M) and guluronic acid (G). The ratio of the two monomers (the 'M:G ratio') and their arrangement in the polymer structure vary from source to source and, to a large extent, control the chemical and physical properties of the alginate. For example, more guluronic segments in the alginate provide a stronger gel or fibre. The two monomers are connected in blocks of M-M, G-G or M-G sequences in the polymer structure. Preferably, the alginate fibres are formed either from High-G alginate having a viscosity of 1% solution of 50-100 mPa or High-M alginate having a viscosity of 1% solution of 40-80 mPa.

Referring to Figure 1, alginate/silver fibres are produced by first dissolving 5-7 % w/w of the sodium salt of the polymer in water, and then mixing 0.1-15 % w/w of a silver nanopowder into the solution so as to produce a dope solution 1. The dope solution is held in a container 2 provided with an inert atmosphere 3, and then the dope is extruded into a coagulating

bath 4 containing a coagulant 5, by means of a pump 6 and a spinneret head 7 completely immersed in the coagulant. The dope is filtered via a filter 8 positioned behind the spinneret.

Figure 2 show a SEM spectrum of the outer surface of a prior art alginate fibre, without metal nanoparticles incorporated therein. Figure 3 shows a SEM image of a similar alginate fibre according to the present invention, comprising 5 % w/w silver nanoparticles; silver nanoparticles and nanoparticle agglomerates can be seen on the outer surface.

Figure 4 shows an alginate fibre according to the present invention having 15 % w/w silver incorporated in the fibre. A higher concentration of particles and particles agglomerates can be seen compared with Figure 3.

Figure 5 is a SEM image of a cross-section of the fibre shown in Figure 4. It can be seen that the silver nanoparticles and agglomerates thereof are distributed throughout the fibre cross-section, and, therefore, that the fibre is a composite material comprising silver nanoparticles incorporated in an alginate matrix.

The present invention provides fibres and other products that may be used alone or in combination, and applications are not limited to those described herein. It will be clear to the skilled person that the method of the present invention can be used to provide polymeric materials for use in a wide variety of bio-medical applications and textile applications, including, for example, mould-resistant products such as tent fabrics, tropical clothing, leisure wear and sportswear.

Anti-microbial fibres may also be used in water filtration systems where, currently, a nylon base fibre is used.

The following Examples further describe the invention

Example 1 (Alginate/silver fibre)

Composite fibres comprising silver nanoparticles incorporated into an alginate polymer were made as follows:

A 500g (5% w/w) high G alginate (supplied by ISP Alginates (UK) Ltd) was dissolved in 470g of water using a high shear

mixer. The dope solution thus formed was stirred for 15-20 minutes and then 5g (1% w/w) nanometric silver powder having a particle size between about 20 and 100nm (particle size distribution d90 < 70nm, d50 < 50nm and d10 < 40 nm) was gradually  
5 added to the dope solution whilst stirring continuously for further 30-45 minutes. (The heat of mixing increased to about 60°C.) The solution thus prepared was vacuum de-aerated and then wet extruded through a filter system (300 wire mesh, non-woven fabric and plain woven fabric) and a spinneret into an aqueous  
10 calcium chloride bath at ambient temperature. After drawing in a hot water bath, the fibres were washed in acetone and finally dried at room temperature.

The alginate/silver fibres so-obtained ranged from a very pale brown colour to a dark brown/black colour. The fibres  
15 exhibited antimicrobial properties.

Example 2 (Cellulose/silver fibre)

35g cellulose wood pulp (Acordis) having a degree of polymerisation similar to pulp used for the manufacture of Lyocell fibres was broken into small pieces and mixed with N-methylmorpholine-N-oxide (NMMO) at 100-120 °C. The mixture was  
20 stirred, using a high shear mixer, for 30-60 minutes to form a slightly coloured 10% w/w polymer solution, or dope. The solution was allowed to cool down to 90-100°C and then 17.5 g (5% w/w) of nanometric silver powder of the same size used in Example 1 was  
25 added gradually into the dope. The dope was stirred continuously, typically for 5 to 15 minutes, so that a homogeneous mixture was obtained. It was found that the process was highly exothermic and the temperature had to be maintained well below 120°C. The final dope (350g) contained 15% w/w total solids.

30 The cellulose-silver fibre was prepared by extruding the hot mixture, under nitrogen pressure (0.3-0.4 MPa), through a filter system (300 wire mesh, fine woven polyester) and a heated spinneret with 35 holes of size 90 micron, immersed in a water coagulant at 55-60 °C. The newly formed filament was then drawn in  
35 a hot water bath at 75-80 °C, wound unto a roller immersed in a

dehydrating agent such acetone and dried on the drum at room temperature, or in an oven at 50-80°C.

The cellulose/silver fibres ranged from a very pale brown colour to a dark brown/black colour. The fibres exhibited antimicrobial properties.

Example 3 (Cellulose/copper fibre)

24.5 g cellulose wood pulp (Acordis) was cut into small pieces and mixed with 322g of NMMO at 100-110 °C. The mixture was stirred, using a high shear mixer, for 30-60 minutes to form a 7% w/w dope. The dope solution was allowed to cool down to 100°C and then 3.5g (1% w/w) of nanometric copper powder with a nominal primary particle size, as determined from specific surface area measurements, of 100 nm was added gradually into the dope whilst stirring continuously, until a homogeneous mixture was obtained. The process was highly exothermic and the temperature had to be maintained well below 120°C. The final dope contained 8% w/w total solids. The cellulose-copper fibre was prepared by extruding the hot mixture (70-100°C) under nitrogen pressure (0.3-0.4 MPa) through a filter system and a heated spinneret (80micron/500 holes) immersed in a water coagulant at 55-65 °C. The filaments thus-formed were drawn in a hot water bath at 75-80°C, collected in a tray containing acetone and dries at room temperature. Alternatively, the filaments were wound onto a roller immersed in acetone before finally dried at room temperature.

The cellulose/copper fibres exhibited antimicrobial and magnetic properties.

Example 4 (Polyacrylonitrile/copper fibre)

This Example demonstrates the versatility of the process; which is applicable to all spun polymer systems (synthetic, regenerated or natural), provided the solutions or melt will not attack the metals.

The dope was prepared by soaking 96g polyacrylonitrile (PAN) fibre (20% w/w) in 383g N,N-dimethylacetamide (DMAC) at about 60 °C until fully dissolved. The solution was then stirred at 60-70°C for 5 minutes with a high shear mixer before gradually adding 2.4g copper powder (0.5% w/w, nominal primary particle size 100



13

nm) and stirring continuously so as to obtain a homogeneous solution. The 40 °C dope thus obtained was then spun into a water/DMAc (30% v/v) bath at room temperature, drawn in a hot water bath and, after winding onto a roller, was left to dry at

5 room temperature.

## Claims

1. A method of producing a polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein, said method comprising the steps of:
  - (i) mixing metal nanoparticles with a polymer dope; and
  - (ii) solidifying the polymer composite from the dope.
2. A method according to claim 1, further comprising the step of adding a dispersant to the dope, so as to control agglomeration of the metal nanoparticles.
3. A method according to claim 2, wherein the dispersant is an alcohol-based dispersant.
4. A method according to any one of claims 1 to 3, wherein the dope is stirred vigorously so as to produce a homogeneous mixture.
5. A method according to claim 4, wherein a high shear mixer is used to stir the dope.
6. A method according to any preceding claim, wherein the polymer composite is solidified by an extrusion process.
7. A method according to claim 6, wherein the polymer composite is extruded to form fibres.
8. A method according to claim 7, wherein the fibres are extruded by a spinning technique.
9. A method according to claim 8, wherein the fibres are extruded by a wet spinning technique.
10. A method according to any one of claims 1 to 5, wherein the polymer composite is solidified by solvent evaporation.
11. A method according to claim 10, wherein the polymer composite is solidified into a film, sheet or membrane.
12. A method according to any preceding claim, wherein the metal nanoparticles have antimicrobial properties.
13. A method according to claim 1, wherein the nanoparticles comprise silver.

15

14. A method according to any preceding claim, wherein the polymer matrix comprises alginate.
15. A method according to any preceding claim, wherein the metal nanoparticles have a size less than 500 nm.
- 5 16. A method according to claim 15, wherein the metal nanoparticles have a size less than 100 nm.
17. A method according to claim 15, wherein the metal nanoparticles have a size in the range 20 to 100 nm.
18. Fibres produced by a method according to any one of claims 1 to 17.
- 10 19. A wound dressing comprising fibres according to claim 18.
20. A fabric comprising fibres according to claim 18.
21. Fibres comprising a polymer matrix having at least one metal incorporated therein, wherein the at least one metal is in the form of nanoparticles.
- 15 22. Fibres according to claim 21, wherein the nanoparticles are distributed in a substantially uniform manner across the fibre cross section.
23. Fibres according to claim 21 or claim 22, wherein the metal nanoparticles have a size less than 500 nm.
- 20 24. Fibres according to claim 23, wherein the metal nanoparticles have a size less than 100 nm.
25. Fibres according to claim 23, wherein the metal nanoparticles have a size in the range 20 to 100 nm.
- 25 26. Fibres according to any one of claims 21 to 25, wherein nanoparticle agglomeration is substantially avoided.
27. Fibres according to any one of claims 21 to 26, wherein the metal nanoparticles have antimicrobial properties.
28. Fibres according to claim 27, wherein the metal nanoparticles comprise Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi, or Zn, or any combination thereof.
- 30 29. Fibres according claim 28, wherein the metal nanoparticles comprise Ag.
- 30 30. Fibres according to any one of claims 21 to 29 having a diameter of less than 500 microns.
- 35

15

31. Fibres according to claim 30 having a diameter of less than 100 microns.
32. Fibres according to claim having a diameter of 10 to 50 microns.
- 5 33. Fibres according to any one of claims 21 to 32, wherein the polymer matrix comprises a synthetic polymer, a natural polymer or any combination thereof.
34. Fibres according to claim 33, wherein said natural polymer comprises alginate.
- 10 35. Fibres according claim 34, wherein the polymer matrix comprises alginate and Ag is present in the polymer matrix in an amount between 0.1 and 15 % w/w, and preferably in an amount between 0.1 and 2 % w/w.
- 15 36. A wound dressing comprising fibres according to any one of claims 21 to 35.
37. A wound dressing according to claim 36, wherein the wound dressing is a non-woven dressing.
38. A polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein.
- 20 39. Any novel feature or combination of novel features hereinbefore described.
40. A process, product or apparatus substantially as hereinbefore described with reference to the accompanying Figures.

25

17

## Abstract

A simple and cost effective method of producing a polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein comprises the steps of (i) mixing metal nanoparticles with a polymer dope; and (ii) solidifying the polymer composite from the dope. Antimicrobial fibres are produced by extruding a dope solution 1 held in a container 2 provided with an inert atmosphere 3 into a coagulating bath 4 containing a coagulant 5, by means of a pump 6 and a spinneret head 7 completely immersed in the coagulant. The dope is filtered via a filter 8 positioned behind the spinneret.

To be accompanied by Figure 1

15

1/5




Figure 1

2/5




Figure 2

3/5




Figure 3



4/5




Figure 4

5/5




Figure 5

From the INTERNATIONAL BUREAU

**PCT**NOTIFICATION CONCERNING  
SUBMISSION OR TRANSMITTAL  
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

LOWTHER, Deborah, J.  
Qinetiq Ltd, IP Formalities  
Cody Technology Park  
A4 Building, Room G016, Ively Road  
Farnborough  
Hampshire GU14 0LX  
ROYAUME-UNI

Date of mailing (day/month/year) 15 March 2005 (15.03.2005)	
Applicant's or agent's file reference IP/P7334/WOD	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/GB05/000261	International filing date (day/month/year) 27 January 2005 (27.01.2005)
International publication date (day/month/year)	Priority date (day/month/year) 28 January 2004 (28.01.2004)
Applicant QINETIQ NANOMATERIALS LIMITED et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable)* The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable)* An asterisk (\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
28 January 2004 (28.01.2004)	0401821.4	GB	25 February 2005 (25.02.2005)

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Vannier James

Facsimile No. +41 22 740 14 35

Facsimile No. +41 22 338 89 65

Telephone No. +41 22 338 8454